Open an account

Beta Bionics

BBNX · NASDAQ

$17.74+$0.90 (+5.34%)TodayMarket closed ·
Prev close $16.84

About BBNX

Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 420 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.

Employees
420
Headquarters
Irvine, California
Listed
Jan 30, 2025
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
betabionics.com

BBNX key statistics

Market cap
957.01M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.00M
Volume
656.76K
Open price
$16.98
High today
$18.06
Low today
$16.87
52 Week high
$32.71
52 Week low
$8.80

Beta Bionics (BBNX) at a glance

As of Oct 20, 2026, Beta Bionics (BBNX) shares are priced at $17.74, giving the company a market cap of 957.01M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $16.87 and $18.06. The current price is 5.2% above the day's low and 1.7% below its high.

Volume so far is 656.76K shares, below the average of 1.00M shares a day.

Over the past year Beta Bionics has ranged from $8.80 to $32.71, and now sits 37% of the way up that range.

Beta Bionics met or beat analyst EPS estimates in 5 of the last 7 quarters. In Q2 FY26 it reported -$0.53 per share against an estimate of -$0.6076.

The average analyst price target is $23.75, 33.9% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

69%of 13 analyst ratings say Buy
  • Buy69.2%
  • Hold30.8%
  • Sell0.0%
Price target · 14 analystsAvg $23.75
Low
$16.16
Now
$17.74
High
$31.92

BBNX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 7 quarters, by 17.3% on average.

  1. Q4 FY24: reported -$2.72 per share against an estimate of -$0.4769
  2. Q1 FY25: reported -$0.93 per share against an estimate of -$0.4855
  3. Q2 FY25: reported -$0.39 per share against an estimate of -$0.4582
  4. Q3 FY25: reported -$0.33 per share against an estimate of -$0.4423
  5. Q4 FY25: reported -$0.29 per share against an estimate of -$0.4238
  6. Q1 FY26: reported -$0.49 per share against an estimate of -$0.4984
  7. Q2 FY26: reported -$0.53 per share against an estimate of -$0.6076

BBNX news

  • Press releaseGlobe Newswire

    BBNX ALERT: Bragar Eagel & Squire, P.C. Urges Beta Bionics, Inc. Investors to Contact the Firm Regarding Their Rights

  • Press releasePRNewswire

    BETA BIONICS, INC. (NASDAQ: BBNX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by November 3, 2026

  • Press releasePRNewswire

    BBNX 2-WEEK DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman

  • Press releasePRNewswire

    Investor Alert: Beta Bionics (BBNX) has been Sued for Securities Fraud Over Alleged Misstatements made to Investors

  • Press releasePRNewswire

    INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Beta Bionics, Inc. to Contact Law Firm

  • Press releasePRNewswire

    Robbins LLP Reminds BBNX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Seeking Lead Plaintiff Status

  • Press releaseGlobe Newswire

    BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit – Hagens Berman

  • Press releaseGlobe Newswire

    BBNX Deadline Reminder: Beta Bionics Investors are Notified to Contact BFA Law before the Expiration of the November 3 Lead Plaintiff Deadline

Similar companies

Companies in the same industry as Beta Bionics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.